engleski

Trastuzumab-induced cardiotoxicity

Cardiotoxicity is a serious side effect of trastuzumab, the humanized monoclonal antibody which is the gold standard in the treatment of early and metastatic breast cancer. In our study followed 171 women with breast cancer (126 early breast cancer and 45 metastatic breast cancer). Symptomatic systolic heart failure was found in 3.2% of women treated with adjuvant and 5.2% in metastatic treatment. Risk factors for the development of trastuzumab-induced cardiotoxicity were basal left ventricular ejection fraction and older age.

trastuzumab; cardiotoxicity

nije evidentirano